# N-AD: Orally Administered Nicotinamide Riboside Over Two Years as a Potential Disease Modifying Treatment for Alzheimer's Disease

> **NCT07741071** · PHASE2 · RECRUITING · sponsor: **Haukeland University Hospital** · enrollment: 270 (estimated)

## Conditions studied

- Alzheimer Disease (AD)

## Interventions

- **DIETARY_SUPPLEMENT:** Nicotinamide Riboside (NR)
- **OTHER:** Palacebo

## Key facts

- **NCT ID:** NCT07741071
- **Lead sponsor:** Haukeland University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08-26
- **Primary completion:** 2030-04-30
- **Final completion:** 2030-04-30
- **Target enrollment:** 270 (ESTIMATED)
- **Last updated:** 2026-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07741071

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07741071, "N-AD: Orally Administered Nicotinamide Riboside Over Two Years as a Potential Disease Modifying Treatment for Alzheimer's Disease". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07741071. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*